All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Details

Target
CD5

Targeting Cell Type
T cell

Targeting Diseases
Acute lymphoblastic leukemia (ALL)

Generation
Second

Vector Name
pCDCAR1

Vector Length
~8kb

Vector Type
Lentiviral vector

Receptor Construction
scFv-41BB-CD3ζ

Discription of Signaling Cassetes
41BB
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
CD3ζ
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

Customize Your CAR Products

Published Data

Complete CAR data FCM

Fig.4 The immunophenotype of CD5CAR T cells.

CAR Construction : H65-41BB-CD3ζ

Fig.4 The immunophenotype of CD5CAR T cells.

The majority of CD5KO anti-CD5 CAR-T cells displayed a naive-like surface phenotype that might have an enhanced capacity for expansion, differentiation, and self-renewal upon antigen stimulation.

Dai, Zhenyu, et al. "The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains." Molecular Therapy 29.9 (2021): 2707-2722. Distributed under Open Access license CC BY 4.0, without modification.

Complete CAR data Cyt

Fig.5 Cytotoxicity assay in vitro.

CAR Construction : H65-41BB-CD3ζ

Fig.5 Cytotoxicity assay in vitro.

Anti-CD5 CAR-T cells exhibited cytotoxicity in vitro when co-incubated with malignant T cell lines with moderate expression of CD5 antigen at relatively low effector to target (E:T) ratios

Complete CAR data FuncS

Fig.6 Cytokine secretion and repeated stimulation assay of CD5-targeting CAR-T cells in vitro.

CAR Construction : H65-41BB-CD3ζ

Fig.6 Cytokine secretion and repeated stimulation assay of CD5-targeting CAR-T cells in vitro.

CAR-T cells produced the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α) and interferon (IFN)-γ and elevated levels of interleukin-2 (IL-2) release when co-incubated with CCRF-CEM cells.

Complete CAR data BI

Fig.7 The in vivo antitumor activity of CD5-targeting CAR-T cells in the tumor model established by CCRF-CEM.

CAR Construction : H65-41BB-CD3ζ

Fig.7 The in vivo antitumor activity of CD5-targeting CAR-T cells in the tumor model established by CCRF-CEM.

A mouse tumor model of T cell acute lymphoblastic leukemia (T-ALL) by tail intravenous injection of CCRF-CEM-ffLuc cells was established to verify the in vivo efficacy of CD5 CAR-T cells.

Complete CAR data BI

Fig.8 The in vivo antitumor activity of CD5-targeting CAR-T cells in the tumor model established by SUP-T1.

CAR Construction : H65-41BB-CD3ζ

Fig.8 The in vivo antitumor activity of CD5-targeting CAR-T cells in the tumor model established by SUP-T1.

A xenograft mouse tumor model was established by SUP-T1 cells with moderate CD5 expression to verify the in vivo efficacy of CD5 CAR-T cells.

CAR scFv data SPR

Fig.9 The binding affinity measurement of H65 antibody to CD5 antigen.

Fig.9 The binding affinity measurement of H65 antibody to CD5 antigen.

The affinity of H65 to recombinant human CD5 was determined using bio-layer interferometry.

More Published Data More Published Data

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.